MLYS
Mineralys Therapeutics, Inc.
$25.65
-0.39%
2026-08-21
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Key Fundamentals
Forward P/E
-10.26
EPS (TTM)
$-4.20
ROE
-80.9%
Profit Margin
0.0%
Debt/Equity
17.72
Price/Book
3.31
Beta
0.68
Market Cap
$2.27B
Avg Volume (10D)
752K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$32.11
60D Low
$22.30
Avg Volume
1.3M
Latest Close
$25.65
Get breakout alerts for MLYS
Sign up for Breakout Scanner to receive daily notifications when MLYS triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Mineralys Therapeutics, Inc. (MLYS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors MLYS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. MLYS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.